- Home
- QNME vs GDTC Comparison
QNME vs GDTC Comparison
Compare QNME & GDTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | QNME | GDTC |
|---|---|---|
| Founded | 2018 | 2018 |
| Country | United States | Singapore |
| Employees | N/A | N/A |
| Industry | Integrated Freight & Logistics | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 11.4M | 10.4M |
| IPO Year | 2024 | 2021 |
Fundamental Metrics
Financial Performance| Metric | QNME | GDTC |
|---|---|---|
| Price | $0.48 | $0.85 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 7.4M | 19.0K |
| Earning Date | 11-18-2026 | 04-24-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 47.83 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $5,850,681.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 111.79 | N/A |
| 52 Week Low | $0.26 | $0.68 |
| 52 Week High | $1.40 | $3.68 |
Technical Indicators
Market Signals| Indicator | QNME | GDTC |
|---|---|---|
| Relative Strength Index (RSI) | 47.78 | 46.00 |
| Support Level | $0.50 | $0.73 |
| Resistance Level | $0.94 | $1.07 |
| Average True Range (ATR) | 0.10 | 0.11 |
| MACD | -0.02 | -0.01 |
| Stochastic Oscillator | 6.26 | 40.00 |
Price Performance
Historical ComparisonAbout QNME Quanome Technologies Inc. Common Stock
Quanome Technologies Inc is a U.S.-based integrated cross-border supply chain solution provider with a strategic focus on the Asian market including China and South Korea.
About GDTC CytoMed Therapeutics Limited
CytoMed Therapeutics Ltd is a pre-clinical biopharmaceutical company focused on harnessing its proprietary technologies to create novel cell-based immunotherapies for the treatment of human cancers. The company's segment include: the business of innate immune cell-based immunotherapy, pluripotent stem cell-based therapy and undertaking the research and development of immune cell and stem cell-based therapy; and the business of processing and banking of cells including cord blood stem cells, research and development on cord blood derived cell-based therapy. Geographically, the company operates in Singapore and Malaysia which is the majority revenue generator.